Philipp Studt is a counsel in the Brussels office of Latham & Watkins and a member of the firm’s Global Antitrust & Competition Practice.

His practice focuses on regulatory aspects of transactions, including foreign direct investment (FDI) control and merger control.

Mr. Studt assists clients in navigating the increasingly complex regulatory landscape comprised of FDI, merger control and foreign subsidies rules in the EU and globally.

He regularly advises clients in sectors seen as sensitive and critical, ranging from technology to energy to healthcare, on the risks and strategy at the outset of a transaction and assists them in obtaining the necessary FDI and merger control approvals. Mr. Studt has navigated some of the world’s most active regulatory regimes, including the EU, Germany, France, Italy, Canada, and Australia.

Furthermore, Mr. Studt’s experience includes advising clients on complex questions around horizontal and vertical agreements and in State aid matters.

Prior to joining Latham, Mr. Studt worked as a senior associate at other international law firms in Brussels and as a consultant at the World Bank (IFC) in Washington, D.C.

Mr. Studt’s experience includes:

  • Assisting US grains merchant manufacturer Bunge Limited in obtaining FDI approvals in nine jurisdictions globally for its planned US$34 billion merger with rival Viterra
  • Obtaining global FDI clearances on behalf of pharma company Norgine Europe in relation to its €1.8 billion sale to Goldman Sachs
  • Advising Syneos Health, a biopharmaceutical solutions organization, on regulatory aspects of its sale to a consortium of private investment firm affiliates
  • Obtaining global antitrust clearances on behalf of global shipping company Ocean Network Express for the US$10.9 billion take-private of Atlas Corporation 
  • Obtaining FDI clearance on behalf of The Carlyle Group in relation to the US$6.5 billion sale of Atotech to MKS Instruments
  • Obtaining global merger control and FDI clearances on behalf of The Binding Site in relation to its £2.25 billion sale to Thermo Fisher
  • Advising biotech company Abcam on FDI and merger control aspects in relation to its planned US$5.7 billion sale to Danaher
  • Obtaining antitrust clearance on behalf of Endeavor for its US$21 billion acquisition of World Wrestling Entertainment (WWE)
  • Advising ArchiMed Group on regulatory aspects of its sale of Bomi Italia, an Italy-based healthcare logistics company, to UPS
  • Advising various financial and strategic investors in German, EU, and multi-jurisdictional merger control and FDI proceedings, including inter alia The Carlyle Group, KPS Capital*, Bain Capital*, and Public Sector Pension Investment Board*
  • Advising Linde AG in global merger control and FDI proceedings in connection with its merger with Praxair*
  • Advising ICON in merger control and FDI proceedings relating to its acquisition of PRA Corporation*
  • Advising Lear Corporation in complex EU merger control proceedings in connection with its acquisition of two seating competitors*

*Matter handled prior to joining Latham

Thought Leadership

  • Co-author of a handbook on FDI control (Handbuch Investitionskontrolle, Manz, June 2022)

Bar Qualification

  • Brussels Bar - E List
  • Certificate of Attestation from Law Society of Ireland
  • New York

Education

  • Master of Laws in International Legal Studies, Georgetown University Law Center, 2012
  • Magister Juris, University of Vienna, 2011

Languages Spoken

  • English